Carbapenem Based Antibiotics Market Scope And Analysis

  • Report Code : TIPRE00027228
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 180
Buy Now

Carbapenem-Based Antibiotics Market Scope, Analysis, and Trends by 2028

Buy Now

Carbapenem-Based Antibiotics Market Report Carbapenem-Based Antibiotics Market Size and Share Carbapenem-Based Antibiotics Market Scope and Analysis

Carbapenem-Based Antibiotics Market Report Scope

Report Attribute Details
Market size in 2021 US$ 3.96 Billion
Market Size by 2028 US$ 5.35 Billion
Global CAGR (2021 - 2028) 4.4%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Type
  • Meropenem
  • Doripenem
  • Imipenem
  • Tebipenem
By Indication
  • Bacterial Meningitis
  • Acute Pelvic Infections
  • Respiratory Tract Infections
  • Intra-Abdominal Infections
  • Urinary Tract Infections
By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Pfizer Inc
  • Savior Lifetec
  • Sumitomo Dainippon Pharma Co Ltd
  • Merck Co Inc
  • Gland Pharma Limited
  • Aurobindo Pharma Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Iterum Therapeutics plc
  • ACS Dobfar S p A

    • Distribution Channel-Based Insights

    By distribution channel, the carbapenem-based antibiotics market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is estimated to register the highest CAGR in the market during the forecast period.

     

    Organic strategies, such as new product launch, is commonly adopted by companies to expand their product portfolios in the market. Moreover, the companies have implemented various inorganic strategies, such as mergers and acquisitions and partnerships. For instance, in May 2021, Gland Pharma Limited in association with Dr Reddy's Laboratories Ltd launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent to generic version of INVANZ (ertapenem for injection) for injection) 1 g/vial, which is approved by the US Food and Drug Administration (USFDA).

    Company Profiles

    • Pfizer Inc.
    • Savior Lifetec
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Merck & Co., Inc.
    • Gland Pharma Limited
    • Aurobindo Pharma Ltd
    • DAEWOONG PHARMACEUTICAL CO.,LTD
    • Iterum Therapeutics plc
    • ACS Dobfar S.p.A
    • Spero Therapeutics